Defendant
2 cases as defendant.
Regeneron Pharmaceuticals, Inc. is a public biotechnology company founded in 1988 and headquartered in Tarrytown, New York. Trading on the NASDAQ under the ticker REGN, the company has a market capitalization of approximately $74 billion as of April 2026 and employs over 15,000 people. For the twelve months ending in March 2026, Regeneron reported revenue of approximately $14.9 billion.
The company discovers, develops, and commercializes medicines for serious diseases. Its major products include Eylea and Eylea HD for eye disorders, Dupixent for allergic and inflammatory diseases, and the cancer immunotherapy Libtayo. Regeneron's research and development process relies heavily on its proprietary VelociSuite® technologies, which are used to produce fully human antibodies for potential drug candidates. The company's pipeline targets a range of therapeutic areas, including oncology, immunology, and rare diseases.
Regeneron's patent litigation posture is that of an operating company defending its key products from competitors. The provided case list shows the company exclusively as a defendant (two cases) and never as a plaintiff, which is typical for an innovative pharmaceutical firm facing challenges from generic or biosimilar manufacturers. Both tracked cases are proceedings before the Patent Trial and Appeal Board (PTAB), a common venue for patent validity challenges.
The notable cases reflect this defensive posture, as they involve biosimilar developers challenging patents for Regeneron's blockbuster drug, Eylea. Both Biocon Biologics, Inc. and Alvotech have filed petitions at the PTAB to invalidate patents related to Eylea and its high-dose formulation. This litigation is part of a broader, multi-front effort by Regeneron to defend the intellectual property of its highest-revenue product against numerous potential competitors seeking to launch their own versions.
Post-Grant Review (PGR) petition filed by Biocon Biologics seeking to join the instituted Alvotech PGR (PGR2025-00085). The petition is substantively identical to Alvotech's and the joinder request is pending.
Post-Grant Review (PGR) proceeding initiated by Alvotech at the PTAB to review the patentability of one or more claims in U.S. Patent 12,168,036. The PTAB has instituted the review, meaning it has found the petitioner met the threshold to proceed.